Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy
Rheumatology International, 08/11/2011
Kwon SR et al. – The findings suggest the low serum Dickkopf–1 (DKK–1) level is related to the pathogenesis of new bone formation in AS, which is resistant to tumor necrosis factor–α (TNF–α) blocking therapy.Methods
- The authors measured the levels of DKK–1, osteocalcin, osteoprotegerin, and C–terminal telopeptide of type I collagen (CTX–1) in patients with AS and in healthy controls at baseline and 3 months after initiating anti–TNF–α therapy in AS patients.
- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores were also measured before and after anti–TNF–α therapy in AS patients.
- Serum levels of DKK–1 were significantly lower in the AS patients than in the controls (P < 0.0001).
- Osteocalcin and osteoprotegerin levels were significantly higher in the AS patients than in the controls (P < 0.0001).
- Serum levels of DKK–1 were not changed after the 3–month anti–TNF–α therapy. Osteocalcin level increased (P < 0.0001), osteoprotegerin level and BASDAI scores decreased (P = 0.025 and P < 0.0001, respectively) significantly after the 3–months anti–TNF–α therapy.
- Serum DKK–1 level was lower in patients with AS than in healthy controls and did not change after 3 months of anti–TNF–α therapy in the AS patients despite the marked improvement in BASDAI scores.